ArticlePloS one2025
Ten years of visual field change in people living with diabetes: A prospective longitudinal study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA better characterization of diabetic retinopathy (DR) may be helpful to monitor early disease, predict progression of DR, and to evaluate new treatment strategies. Visual function has been suggested to complement the assessment of microvascular lesions in DR but needs to be evaluated in longitudinal studies.
objectivesThis prospective longitudinal cohort study investigated whether early visual field deterioration in diabetes is associated with change in DR, and whether known risk factors as diabetes duration and glycated A1c (HbA1c) affect the visual field.
methodsPeople living with diabetes, 18 to 75 years of age, were consecutively recruited from the local DR screening program. Individuals with eye diseases other than DR that could affect the visual field, and those who had received previous local eye treatment for DR, could not be included. Participants who had completed a five-year follow-up were re-examined after nine and ten years from baseline. The most important outcome was deterioration in series of visual fields as determined by an experimental model tailored for people living with diabetes. Stages of DR were evaluated according to the Early Treatment Diabetic Retinopathy Study (ETDRS) scale, and glycemic control by measurement of HbA1c.
resultsFifty-six participants (median age 69 years at the last visit, 35 males) completed 608 out of 616 scheduled visits during ten years of follow-up. Progression and regression of DR occurred most often between no (ETDRS level 10) and minimal (ETDRS level 20) DR. The number of deteriorated test points increased annually by 11% (95% CI: 6.9-15.3) and were not associated with change in DR but with higher levels of HbA1c.
conclusionsEarly deterioration of visual function occurred independently of DR and was associated with worse glycemic control, suggesting that the metabolic disturbances due to diabetes induced a primary deterioration of sensitivity in the visual field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.